New Research Targets MD2 to Curb Prostate Cancer Spread

Preclinical study shows MD2 inhibition reduces tumor growth in prostate cancer bone metastasis model

Apr. 2, 2026 at 6:12am

Got story updates? Submit your updates here. ›

Researchers have published new findings in Oncoscience that identify the protein MD2 as a potential therapeutic target and biomarker for metastatic prostate cancer. The study shows high MD2 expression is linked to increased metastasis, immunosuppression, and resistance to PARP inhibitor therapy. Preclinical data also demonstrates that pharmacological inhibition of MD2 can reduce tumor growth in a mouse model of prostate cancer bone metastasis.

Why it matters

Prostate cancer metastasis, particularly to the bone, is a major driver of mortality. These findings suggest targeting the MD2 protein could lead to new treatment approaches to curb the spread of prostate cancer and potentially predict response to certain therapies.

The details

The research perspective was led by co-first authors Melina A. Dattilo from Universidad de Buenos Aires and CONICET–Universidad de Buenos Aires, and Marina G. Ferrari from Rush University Medical Center, with corresponding author Adrian P. Mansini also from Rush University. The authors built on prior work identifying MD2/LY96 as a biomarker linked to poor prognosis and metastatic potential in prostate cancer. Their new preclinical data shows pharmacological inhibition of MD2 reduced tumor growth in a mouse model of prostate cancer bone metastasis.

  • The research perspective was published on March 11, 2026 in the journal Oncoscience.
  • The study analyzed patient tumor tissues and presented new preclinical data on MD2 inhibition.

The players

Melina A. Dattilo

Co-first author from Universidad de Buenos Aires and CONICET–Universidad de Buenos Aires.

Marina G. Ferrari

Co-first author from Rush University Medical Center.

Adrian P. Mansini

Corresponding author from Rush University Medical Center.

Oncoscience

The journal that published the research perspective.

Rush University Medical Center

The institution where two of the study authors are affiliated.

Got photos? Submit your photos here. ›

What they’re saying

“These findings support MD2 as a novel therapeutic target and identify soluble MD2 as a promising predictive and prognostic biomarker in metastatic PCa, with mechanistic links to immune evasion and inflammatory signaling.”

— Adrian P. Mansini, Corresponding author

What’s next

The authors note that these findings remain preclinical and require further validation in additional models and clinical cohorts. Next steps include testing MD2 inhibition in broader prostate cancer systems, clarifying how MD2 shapes immune evasion and bone colonization, and evaluating whether soluble MD2 can serve as a practical biomarker for treatment response and metastatic burden.

The takeaway

This research highlights the potential of targeting the MD2 protein as a novel approach to curbing the spread of prostate cancer, particularly to the bone. The identification of soluble MD2 as a potential biomarker could also help predict metastatic risk and response to certain therapies, representing an important step forward in managing this deadly disease.